Johnson & Johnson (JNJ)

They have combined for 118 years of consecutive dividend increases.

It's hard to argue against its reliability.

Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

These companies are built to last. And their stocks are built for owning over the long term.

These longtime market beaters may not have peaked yet.

These companies are leaders in their fields.

This pharma stock is cheap for a reason.

Healthcare companies with different market caps offer different rewards and challenges.

Plains GP Holdings runs a major North American network for crude oil and NGL transport and storage, serving producers and refiners.

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

Intuitive Surgical has already made many of its early investors wealthy.

Solid results weren't impressive enough to move the stock price higher.

This once-beaten-down pharma stock remains an intriguing turnaround story.

These companies boast significant upside potential.

The blue chip dividend stock is quietly growing again as a streamlined company.

Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

Johnson & Johnson (NYSE:JNJ) reports upbeat earnings for Q1, with higher sales and raised fiscal 2026 guidance. Some analysts raise price targets.

Johnson & Johnson reports strong Q1, beating expectations and setting the stage for future growth. Analysts maintain Buy rating.

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of